Hyperuricemia
153
9
16
92
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
13 trials with published results (8%)
Research Maturity
92 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.9%
6 terminated out of 153 trials
93.9%
+7.4% vs benchmark
18%
27 trials in Phase 3/4
14%
13 of 92 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 92 completed trials
Clinical Trials (153)
Chronic Kidney Disease and Metabolic Disorders in the Elderly
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With "Four Highs" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia)
Treat-to-target by Email During Urate-lowering Therapy in Gout
A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Effectiveness of Digital Health Intervention on Community Health Care in Middle-aged and Older Population in Taiwan
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients
Imagery as Biomarker of Gout
This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Order to Evaluate the Need of Adjuvant Uric Acid Lowering Therapy
Effects of Fibres Combined With Probiotics on Uric Acid in an ex Vivo Fermentation Model
Clinical Effect Observation of Barley Green Intervention in Hyperuricemia Population and Related Mechanism Study of Xanthine Oxidase
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
Relationship Between Intestinal Flora Changes and Hyperuricemia Under Chronic Psychological Stress
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)